Member Info for ratcliffewriter

Buys look to outnumber sells by about 10 to 1 so far, and I've been offered 7.08 for in excess of 200k. In the medically induced absence of C7 I have to say it looks as if the non existent appetite for shares from the mythical buyer (or buyers indeed) has not evaporated, and money continues to be invested here.

It's a great quote, but no, I didn't actually know it was George Best or if I had known then I'd forgotten. The only famous footballer quote I know is 'I've got me fishing rod and some chicken, ah reckon ah can talk to him if they'll let me.' Courtesy of a rather disconnected Paul Gascoigne during the hunt for that murderer. I think he was muttering about 'lifestyle companies' at the same time, but then he was never the sharpest tool in the box either.

True C7, but the other side of the coin is that if I had kept my money out of Scancell and awaited a lower share price, while I would have been able to buy many more shares for each pound, the reality is that I would probably have spent a good proportion of the money of high living, loose women, fast cars and expensive food. The rest I would probably just have wasted.

My thanks also for the 07.34 post - I had started watching it and was thinking how good it was and about the non-exclusive agreement just announced, and then noticed it is 3 or 4 years old. I imagine that with pushier PR, this sort of presentation science could have got Lindy onto the BBC breakfast news where so many much-heralded treatments end up, but then end (as they do) with the words 'these are early days and we will have to see where this leads', or words to that effect. In the video, Lindy talks of a period of several years being needed (or words to that effect), a period that has now elapsed. So while the time taken to get the platforms off the ground is frustrating for us mere mortals on the sidelines, I would far rather the situation we have, where we start to get PR when the platform is tying itself to 'major players' and people are able to consider some serious commercial action in relation to it, rather than having a blare of publicity, a big sp spike, then silence. Or instead of silence, some ever-feebler PR to try to keep momentum going, which would use time and resources which would be (and have been) far better spent in working on the science proper, until there is something seriously joined up that may sustain itself in the publicity stakes. Sentiment among the balanced posters seems to indicate that such a watershed may be fast approaching, but as ever time will tell.

Thanks for the direct link C7 - within that page it says '...has the potential to initiate an anti-tumour immune response following the secretion of damage-associated molecular patterns (DAMPs), leading to long-term tumour control.' So that's where Team DAMP hide out then....

7 recs for my post indeed. And there was me thinking recs were just contrived additions and part of some conspiracy to make posters feel good, or is this a 'pick and choose' matter, depending on the recipient? Presumably I have 7 people in my 'support gang' - how refreshing, if a bit of a fantasy.
On a different line, I find the concept and progress thus far of Avidimab to be very interesting, and possibly a candidate for 'left field' news. Anyway, I shall be signing autographs and receiving the adulation of my fan club at the AGM, provided no other members of my family meet with a sticky end as happened last time I was planning to go.

Just pondering a few things since the Avidimab RNS - Given that the science in it is a 'booster' to an antibody (and setting aside its potential applications to Scancell's own products), that means in very simple terms that anyone who wants their current antibody treatment to have added avidity can experiment with Avidimab as a 'bolt-on to that established treatment. Therefore the ability to go into a non-exclusive partnership is presumably pretty tempting if it looks right, and initial outlay would be relatively small to the existing manufacturer, but if the Avidimab technology worked for them, not only would it add significant avidity to an already (potentially) proven product, but it would also allow the restart of all patent timings with a new formulation of a known drug which would, all being well, allow the manufacturer exclusive protected rights while also leaving all generics of the old formulation way behind and potentially redundant. Extrapolating that further, such agreements would provide a basic upfront payment to Scancell, ensuring enduring financial stability. Now wouldn't that be a great situation,? And if my ponderings are correct, or in the right area, what would that do to the SP I wonder. Not crystal-balling, just thinking aloud, and ready for correction, expansion or shooting down in flames.

That was always one of their more ludicrous allegations. That's the sort of thing that undermines their credibility.

Can't help but think there's something of urgent interest in this new platform when it has gone from University spinoff a year ago to announcement just those 12 months later, and the announcement already has a partnering, and it is non-exclusive. Is there a bit more of a commercial stirring around this one than there was around the other platforms? I like their style here. (Or is it 'I life their style', as Eeyore might say?)

I suppose a lot depends what he's having shoved in where, thus affecting his ability to concentrate on posting.

TF - you need to read back through the posts - my 0900 'C7 is in hospital for the day.'.

The ask has just gone up - maybe some available at the new higher price?

Had a look back to a post of his from the other day - he put '...they are now paying more than 7.10 which was what I was hoping for, to begin a bull run, now lets see whether the MMs release there hold on the bid to over 7p.'
The man may medical complaints, but he also seems to have at least one crystal ball.

Just thought I'd mention there have been a couple, since nobody else has.

CH is quoted on Proactive as saying 'Our first collaboration and evaluation agreement with one of the major players in the antibody development field is a significant achievement in such a short period of time and we believe our novel AvidiMab enhanced cell killing platform has broad partnering potential.'
A collaboration in a short period of time with broad partnering potential sounds very exciting. As said before, it would be good to know who the 'major player' is, and also nice to have a second or further collaboration announced soon. Presumably more than one NDA on the go then....

So you agree a buyer exists?

Looking on nex it seems C7's buyer (who Knowlesi says doesn't exist) has had 289,000 at 7.425 as well. C7 did say it would happen when the bid went back over 7.

C7 is in hospital for the day. No doubt would be delighted with the rns, and also a rising bid makes it look like the non-existent mythical buyer will be around today. Same as the last few weeks. Interesting the 10k buy at 7.425 is well up on the 7.18 paid on Monday.

So how come the volte face from being quite happy that scancell will come good but having just a longer time line than others, suddenly turning to a totally dismissive 'lifestyle' comment? And surely you qualify as King of the Rampers by admitting to making a grossly 'buy buy buy' post on a share that then spiked, presumably allowing you to sucker people in while you cashed out with a smirk on your face, before it then crashed. Doesn't that make you the lowest form of life on a bulletin board?
Anyway, glad to see you remember my posts from ages ago - you must think about me a lot.

It wasn't a poor choice of words - it was a short clear direct statement with the words 'all the evidence points to' added. But as ever, no evidence offered. It's a serious accusation that needs backing up or withdrawing. Knowlesi is the one who so hates unsubstantiated comments. But I'm guessing it will be the usual silence until anything he wants to avoid has sunk down the list of posts. We shall see.